Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorOslo University Hospital
About this trial
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age > 18 years
confirmed diagnosis of peritoneal surface malignancy
candidate for CRS-HIPEC
written informed consent
Disqualifiers
none
Trial population
All patients with PSM that are referred to Oslo University Hospital and are candidates for CRS with HIPEC may be included in the study.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Observational study.
Other interventionAnalysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor. HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.
Treatment groups
300 Participants
are divided into 1 treatment groupGroup A: Observational study1 intervention
Trial outcomes
Primary outcomes
1
Overall survival (OS)
Time from surgery until death from any cause
Time frame
5 yearsSecondary outcomes
1
Disease-free survival (DFS)
Time from surgery until disease recurrence or death
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Oslo University Hospital
Lead sponsor
The Research Council of Norway
Collaborator
Source ClinicalTrials.gov